Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
← catalyst calendarNCT07132567 · readout ≤ 773 d
Sponsored by Kyowa Kirin Co., Ltd. (industry) · 4151.T — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
15estimated
Sites
6
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-02 | actual | When the study began enrolling |
| Primary completion | Sep 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mycosis Fungoides
- Sezary Syndrome
Intervention
- Drug: Poteligeo 20mg — also filed as Mogamulizumab
Primary outcome
what the primary-completion date above is the date OFSafety (Special situation, adverse event, symptom, or disease occurring during treatment with Poteligeo)
measured From first administration of Poteligeo through 90 days after the last dose
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed